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Summary.-A series of xenografts of human breast carcinomas has been established
and serially transplanted in immune-suppressed mice. Certain structural and
functional features of the original human tumours, including carcinoembryonic
antigen and epithelial membrane antigen, continue to be expressed by the resulting
xenografts. Stromal responses such as elastosis and oestrogen-receptor activity
were lost by the xenografts. No metastases were detected in tumour-bearing mice.
This study suggests that xenografts may have some value in experimental pathology
as one type of model of human breast carcinoma.
HUMAN TUMOURS have been successfully
transplanted to a variety of animal hosts,
in particular the congenitally athymic
(nude) mouse (Rygaard & Povlsen, 1969;
Shimosato et al., 1976; Giovanella & Fogh,
1978) and the artificially immune-sup-
pressed mouse (Castro, 1972; Steele et al.,
1980). Using mice immune-suppressed by
thymectomy at 4 weeks of age and subse-
quently exposed to 9 Gy whole-body
irradiation protected by prior 200 mg/kg
cytosine arabinoside (Steele et al., 1978)
we have established a series of 9 serially
transplantable xenografts ofhuman breast
carcinomas. The extent to which the
xenografts resemble structurally and func-
tionally the human tumours from which
they were derived has been assessed by
using both conventional histological and
immunohistochemical methods.
MATERIALS AND METHODS
Immune-suppressed mice.-Female CBA/
lac mice were immune-suppressed by thym-
ectomy at 4 weeks of age, followed 4 weeks
later by9 Gywhole-bodyirradiation delivered
by a 60Co source. The mice were protected
against the otherwise lethal effects of this
radiation dose by an i.p. injection of 200 mg/
kg ofcytosine arabinoside 48 h before irradia-
tion (Millar, 1976). These mice were used for
the original (human-to-mouse) passage and
for all subsequent (mouse-to-mouse) passages.
Tumour material.-Fresh specimens of
human breast carcinoma were obtained at
surgery from patients undergoing operations
for breast carcinoma at the Royal Marsden
Hospital, Sutton. Tissue was obtained from
the primary tumour and metastatic deposits
in lymph nodes, liver, skin and other sites.
When progressive tumour growth occurred in
a mouse at the site of implantation of a
human breast carcinoma, the mouse was
killed, and the tumour excised. A portion of
the tumour was sent for karyotyping and for
histology, and the remainder transplanted
into as many freshly immune-suppressed
mice as the tumour bulk permitted.
Tumour implantation.-For implantation,
tumours (whether primary, metastatic or
xenografts being passaged) were cut into 2mm
cubes and inserted into an s.c. tunnel on the
ventral aspect ofthe mouse. The skin incision
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was then closed with a metal clip. All opera-
tive procedures were performed under ether
anaesthesia in a laminary down-flow cabinet.
Necropsies.-All tumour-bearing mice were
examined for macroscopic evidence of meta-
stases to local lymph nodes, liver, lungs and
spleen. In a proportion of mice, these organs
were processed for light microscopy. Serial
sections were prepared, sectioned and stained
in an attempt to detect microscopic evidence
of metastatic spread.
Oestroqen receptor (RE) assay.-Most ofthe
primarv tumours were frozen in liquid N2
at surgery for later assay. Xenografted speci-
mens were excised, snap-frozen in liquid N2
and assayed for oestrogen receptor. The dex-
tran-coated charcoal assay was issued for all
specimens, using Scatchard analysis (Korsten
etal., 1975).
Tumour volume measurement.-Implanted
tumours were measured twice weekly from
the time when progressive growth began. Two
diameters were measured with vernier calipers
calibrated to 0-1 mm, and volume calculated
as for an ellipsoid, V=7rLD2/6.
Histological techniques.-Tumour specimens
(original human tumour and xenografts) were
fixed in neutral formalin or Bouin's solution,
conventionally processed and embedded in
paraffin wax and sectioned at 5 Hm. Sections
were stained with haematoxvlin and eosin,
periodic-acid-Schiff and elastic-van Geison.
In addition, immunohistochemical methods
were used to demonstrate carcinoembryonic
anitigen (CEA), epithelial membrane antigen
(EMA; Heyderman et al., 1979; Sloane &
Ormerod, 1980) and lactalbumin, using
appropriate monospecific antisera and re-
agents as described previously (Heyderman
& Neville, 1976; Stevens et al., 1978; Sloane
and Ormerod, 1980).
RESULTS
The successful xenografts and the "take
rate" of the human breast carcinoma
specimens are shown in Table I. It should
be noted that a successful take was defined
as progressive growth of a tumour (subse-
quently shown to be of human breast
carcinoma origin) which could be serially
transplanted into further mice. Histo-
logical evidence of "viability" in a static
nodule was not counted as a take. About
1 patient in 10 gave rise to a transplant-
TABLE I.-Xenografts established as a
function ofinitial tumour material
Number of
Speci- Im- Lines
Nature of specimen mens* plants resulting
Primary breast carcinoma 60 2024 9
Lymph-node metastases 18 564 0
Cutaneous metastases 8 160 0
Hepatic metastases 4 164 0
Ascitic or pleural
effusions 6 28 0
Totals 96 2940 9
* The 96 specimens were derived from a total of 76
female patients.
able xenograft line, but even in successful
xenografts 80-90% of the tumour cubes
implanted failed to grow in the first
passage.
A variety of manoeuvres designed to
improve the take rate was attempted,
including the use of nude mice, increasing
the dose of irradiation to 10 Gy, implant-
ing tumours under the renal capsule, i.m.
and i.p., injecting tumours in a fine brei,
implanting larger volumes of tumour and
supplementing the mouse with oestrogen
and progesterone injections. There was no
evidence that any of these manoeuvres
increased the take rate. Details of these
and other manipulations have been pub-
lished elsewhere (Bailey et al., 1980a).
Successful xenografts began progressive
growth in their first passage after a lag of
12-46 weeks after implantation. Once
progressive growth began, it continued in
an exponential manner until the tumours
became so large that the animals had to be
killed. Volume-doubling times in the first
passage ranged from 14 to 70 days. On
subsequent passages, the lag became
shorter, and stabilized after 3-5 passages
at 2-5-12 weeks. The doubling time also
shortened, and tumours from the same line
tended to become more uniform in their
growth pattern (Table II).
Mice in which xenografts failed to grow
were observed for at least one year before
a negative take was scored. No non-human
tumours arose at the implantation site,
although an adenocarcinoma arose in the
submandibular region of one mouse,
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distant from the implanted breast car-
cinoma.
Serial passaging of all xenografts has
TABLE II.-Lag period, volume-doubling
time and number of passages of 9
xenografts
Lag period
HX (wks)
designa- , P
tion PI PIII
15
28
32
34
28
22
20
26
12
3
4
12
5
4
4
3
6
3
99
100
101
102
104
105
106
107
108
Doubling
time (days)
- No. of
PI PIlI
22 8
18 7
70 26
36 12
30 11
20 10
17 5
27 12
14 6
passages
12
5
3
5
12
3
10
9
4
PI=human-to-mouse passage.
PIII=second mouse-to-mouse passage.
been performed. The slowest-growing
xenograft (HX 101) has been passaged
x 3 and maintains a long lag period
(12 weeks) a slow volume doubling time
(26 days), and a low take rate (- 20%).
Other tumours have been passaged up to
12 x (Table II).
The karyotypes of the xenografted
tumours have been studied. Although
occasional murine chromosome spreads
were seen, all tumours were predominantly
composed of human cells, with a modal
chromosome number ranging from 60 to
90.
Four of the 8 primary tumours from
which xenograft lines were established
were oestrogen-receptor-positive. Thev
were cases 3, 4, 7 and 8 (Table III) with
values of 79, 123, 54 and 17 pmol RE/mg
TABLE III.-CoMparison of the histological features of the original human mammary
carcinomas and the resulting xenografts*
Case
Carcinoma Antigen expression**
t - , A_-- N
No. Source§
1 Original
Xenograft-
2 Original
Xenograft-
(HX No.)
-P1 (105)
-P1 (102)
P2
P3
3 Original
Xenograft-P1 (101)
P3
4 Original
Xenograft-P1 (100)
P3
5 Original
Xenograft-P1 (106)
PIO
6 Original
Xenograft-PI (107)
7 Original
Xenograft-P1 (99)
P2
P3
P1l
8 Original
Xenograft-P1 (108)
Typet
ID
I ID
ID
I CO
ID
ID
ID
ID
ID
AM
AM
AM
ID
CO
CO
MA
MA
ID
CO
ID
ID
ID
ID
ID
Grade$
II
II
III
III
III
III
II
III
III
III
III
III
II
III
III
CEA EMA
+ ++
++ ++++
++ ++++
+ ++
_ +
Stroma**
Desmo-
plasia Elastosis
+_
++ +
++ +++ +++ ++
++ ++ + _
_ + +__
+ ++
++
+ ++
+
++
++
+
+ ++
++ ++
III
III
III
III
III
III
III
+
+
+
+
+
++
++
+
+
+++ +++
-+
+
+
_ ++
+
_+
* HX104 was not included in this table, as insufficient primary tumour remained for the complete staining
procedure for comparative analysis with the resulting xenograft.
t ID =infiltrating duct carcinoma; MA =mucus-secreting adenocarcinoma; AM=atypical medullary
carcinoma; CO =comedocarcinoma.
: Bloom & Richardson (1957).
§ P1 etc. =No. of xenograft passage.
** Arbitrary scale (± rare positive cell).
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FIG. 1.-Xenografts of Case 3 carcinoma. The tumour cells form large duct or tubule-like structures
separated by fine fibrovascular trabeculae. Most ofthe tubules are solid; a few show acinar develop-
ment.H.&E. x125.
FIG. 2.-Xenografts of Case 1 carcinoma. The tumour cells form short cords or solid duct-like
structures very reminiscent ofone form ofinfiltrating duct carcinoma commonly found in patients.
Nuclear pleomorphism is prominent. H. & E. x 190.
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FIG. 3.-Xenografts of Case 6 carcinoma. Islands of tumour cells are present in the midst of
"lakes" of mucus and reveal a pattern characteristic of mucus-secreting mammary carcinomas.
H. & E. x 190.
FIG. 4. Xenografts from Case 2 showing a comedocarcinoma-type pattern, with central necrosis and
a peripheral ring of viable tumour cells. Rodent skeletal muscle is seen at the foot of the illus-
tration. Note the darker spindle-shaped cells of the duct; these appear to be myoepithelial in
type. H. & E. x 190.
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FIG. 5.-A portion of a duct from a comedocarcinoma from Case 2 with an area of central necrosis
(above). The epithelial tumour cells were of two types: one was large, polyhedral with an open
cytoplasm and showed nuclear pleomorphism. The other was smaller and splheroidal, with eosino-
plhilic cytoplasm and a central nucleus. Mitotic activity is seen. Mlyoepithelial-like differentiation
with the formation of spindle-shaped and elongated dark-nucleated cells is seen at the periplhery
of the duct and in areas in its substance. H. & E. x 300.
tumour cytosol protein respectively. None
of the xenografts contained detectable
levels of RE.
No metastases were seen macroscopic-
ally in over 2000 tumour-bearing mice.
No microscopic evidence of metastasis was
seen in the liver, lungs or spleen of the
100 mice in which these organs were
sectioned and examined histologically.
Sections were also stained immunohisto-
chemically for EMA, a method which has
been used to visualize micrometastases in
human organs (Sloane et al., 1980a, b).
This also failed to reveal any metastatic
deposits.
The gross appearance ofthe xenografted
tumours varied slightly from one line to
another, but remained constant within
each line. All the tumours appeared to be
well circumscribed. Larger tumours be-
came attached to, and ifallowed to, would
ulcerate through the skin. The blood
supply was derived from the host, andlarge
vessels could be seen entering and leaving
the tumour. Larger tumours developed
areas of central necrosis. Tumours would
grow to over 2 cm in diameter, but this
was not routinely allowed for humane
reasons.
The histological features of the mam-
mary carcinomas implanted in mice and
which grew progressively therefrom are
shown in Table III. All were infiltrating
duct carcinomas (Figs 1 and 2) with two
exceptions, viz. Cases 4 and 6 (Table III),
which were an atypical medullary car-
cinoma and a mucus-secreting adeno-
carcinoma (Fig. 3) respectively. Most of
the tumours, as first-generation trans-
plants, recapitulated the histological
appearances of the original tumour mate-
rial (Figs 1-3). In some instances there was
a tendency for the xenografts to become
less differentiated (Grade III), with the loss
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FIG. 6. Case 3 . An immunoperoxidase stain for the epithelial membrane antigen (EMA) in a tubule-
like structure, showing expression of the antigen on the luminal membrane of ducts and in the
cytoplasm of some tumour cells. Haemalum counterstain. x 280.
of ducts or acini and formation of sheets
and cords of cells, with occasional giant
and bizarre forms. In 3 instances (Cases
2, 5 and 7; Table III) microscopy showed
that the xenografts formed a series of
rounded "ducts" or "spheroids", some
with central necrosis; the histological
pattern was that of comedocarcinoma
(Figs 4 and 5). Such spheroids were each
surrounded by a connective-tissue capsule
which extended in to surround each focus
of comedocarcinoma.
Within such ducts and foci of comedo-
carcinoma there was evidence of cellular
differentiation, as shown by the presence
of more than one morphological type of
tumour cell (Fig. 5). At the periphery,
dark elongated fusiform nucleated cells
rich in chromatin were present, which on
occasions extended in toward the centre
of the duct in a tongue-like manner. Pre-
liminary electron-microscopic studies sug-
gest that they are myoepithelial-type cells
(Hamperl, 1970; data not shown). The
remaining cells were epithelial and of two
morphological types. One consisted of
small spheroidal cells with pale eosino-
philic granular cytoplasm and single
rounded nuclei containing a central nucle-
olus. The other was a larger rounded cell
with pale, rather empty, cytoplasm, a
prominent cell membrane and a central
vesicular nucleus. While the proportions
varied from ductule to ductule, the smaller
form ofcell type tended to predominate.
Most of the tumours were surrounded
by a thin connective-tissue capsule; a few
were not and showed local invasion of the
related skeletal muscle. The stromal
features of the xenografts were different
from the original tumour material. While
many formed an infiltrating duct carcino-
matous pattern with a cord-like arrange-
ment of the tumour cells separated by
fibrovascular trabeculae (Fig. 2), none
exhibited a prominent desmoplastic res-
ponse. Stromal elastosis was not seen,
except at the centre of one xenograft
(Case 6, Table III) which was judged to be
a surviving portion of the original trans-
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FIG. 7.- .Case 3. An immunoperoxidase stain for carcinoembryonic antigen (CEA) showing the cyto-
plasm of many tumour cells forming duct-like structures. Note the negative stroma. Haemalum
counterstain. x 175.
planted tumour. Calcification involving
the stroma and/or in the ducts was seen
only once (Case 4, Table III).
The epithelial membrane antigen (EMA)
was expressed by all the primary breast
carcinomas and by all the resulting xeno-
grafts (Fig. 6). Although the staining
intensity, and hence possibly the degree of
EMA expression, varied from tumour to
tumour, the distribution in the primary
lesion and the xenograft was identical.
It was found to be expressed by almost
all the tumour cells and was detectable
in their cytoplasm, in intracytoplasmic
lumina where they were formed and on
their luminal membranes, where the
tumour cells formed acini or ducts. Nec-
rotic debris in such ducts could also
contain the antigen. The expression of
EMA continued in tumours throughout
various subsequent xenograft passages,
though its intensity as judged on an
arbitrary scale, and the number ofpositive
cells, tended to decline with passage
(Table III). The carcinoembryonic antigen
was also expressed by all but one of the
primary tumours but the intensity of
staining was always less than for EMA.
Moreover, its expression was always focal,
many tumour cells being negative. CEA
tended to be more prominent in tumour
cells situated towards the periphery ofthe
primary carcinoma. Its cellular topo-
graphical distribution in the primary
tumours and resulting xenografts, how-
ever, was similar, and akin to the location
of the EMA being detected in the cyto-
plasm (Fig. 7), luminal surface of cells
forming ducts or acini and in the necrotic
debris which they could contain. Most
xenografts recapitulated this pattern,
though CEA activity was lost in some by
the first transplant generation (Table
III). Both antigens could be expressed by
the sameepithelial cell, bothintheprimary
tumours and the xenografts. None of the
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primary tumours or their xenografts
expressed lactalbumin.
DISCUSSION
Many facets of the biology of human
breast cancer remain obscure and ill
understood. One approach to attempt to
improve our understanding ofthis disorder
or group of related disorders is to develop
appropriate model systems. The ability to
grow some human tumours in suitably
immunologically deprived animals may
offer one form of model system. Such
experimental xenograft systems, however,
to be useful, need to continue to express
the structural and functional properties
of the primary tumours from which they
were derived and to metastasize to distant
sites.
This present study has confirmed other
related studies that it is possible to
establish human breast carcinomas as
transplantable xenografts in immune-
suppressed rodents. In most instances,
their histological features showed a re-
markable similarity to the carcinoma
from which the xenografts were derived
(Figs 1-5; Table III). Nevertheless, in
some of the first-generation transplants
and increasingly with further passage,
there was a tendency for the tumours to
become less differentiated, withfewerducts
or acini, increased mitoses, nuclear pleo-
morphism and atypia. Despite this, how-
ever, the xenografted carcinomas con-
tinued to resemble certain aspects of
human breast-tumour morphology. Two
tumours, a mucus-secreting adenocar-
cinoma and an atypical medullary car-
cinoma, also retained their morphological
features as xenografts (Fig. 3).
Of particular interest were the tumours
from Cases 2, 5 and 7 (Table III).
As xenografts such lesions showed a
distinct tendency to grow as encapsulated
spheroids, with the formation at a histo-
logical level of a classical comedocar-
cinoma pattern (Figs 5 & 6). Moreover,
such lesions showed evidence of morpho-
logical differentiation to form different cell
types lining such ducts. There would
appear to be two different types of
epithelial cell, whilst the smaller dense-
nucleated cells situated at the periphery
may be myoepithelial in type. Preliminary
ultrastructural studies support these
conclusions, but further work on their
functional properties is needed to confirm
them. In an examination of the primary
lesions removed from the patients, whilst
myoepithelial cells were readily identified
in the intraductal portions, they were not,
obvious in the infiltrating duct-like areas
of the lesions. Myoepithelial cell differen-
tiation, however, has been recorded in both
primary and metastatic human mammary
carcinomas (Hamperl, 1.970; Sarker &
Kallenbach, 1.966).
Recently, Rudland et al. (1980) have
isolated a stem-cell line from a DMBA-
induced rat mammary carcinoma, and
shown that it is able to differentiate to
form either secretory epithelial cells or
myoepithelial-type cells in culture. Thus,
it is possible that the stem cells of the
xenografts which form comedocarcinoma-
like structures (as opposed to the stem
cells ofthe other xenografts) still retain the
ability (either endogenous or induced by
the rodent environment) to form ducts,
the component cells of which have differ-
entiated along both myoepithelial and
epithelial pathways. The myoepithelial-
like cells, however, can be found with
other cells in the wall of the ducts distant
from the periphery wvhich is their normal
location.
While the xenograft tumours continue
to express certain antigens also found in
primarv and metastatic humaan breast
tumours, there is a tendency to lose them
with serial passage. As all the primary
lesions expressed EMA and most, but not
all, CEA, these properties do not appear to
be related to their subsequent ability to
become established as xenografts. None
of the xenografts or their parent tumours
expressed lactalbumin, a finding at vari-
ance with the data ofWalker (1 979).
Other functional features expressed by
the primary breast carcinomas, however,
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were lost when established as xenografts.
These include the prominent desmoplastic
stromal response and elastosis so typical
of many breast carcinomas, and also the
expression of the oestradiol-receptor com-
plex. Moreover, despite ameticuloussearch
and even following the i.v. injection of
single-cell suspensions of the xenograft
tumour cells into the tail veins ofimmune-
suppressed mice, no spontaneous or arti-
ficially induced metastases were found.
In conclusion, it would seem not un-
reasonable to propose that the present
xenografted human mammary carcinomas
represent potentially useful model sys-
tems. It is possible to envisage their use
in studies of aspects of cell differentiation
and the control of growth, together with
others aimed at deriving improved thera-
peutic regimes or localization methods
through the use of radiolabelled appro-
priate antibodies (Moshakis et al., 1980).
We thank Mrs K. Steele who prepared the antisera
and made the enzyme conjugates. M. G. Ormerod
was supported by a project grant from the Medical
Research Council.
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